<b>Bioequivalence Study of Fentanyl Tape for 1 Day without Use of Antinarcotic in Healthy Male Japanese Subjects </b>

DOI Web Site 2 References
  • KIJIMA Koji
    Clinical Research Operation Department, Development Division, Meiji Seika Pharma Co., Ltd.
  • SHIMADA Ken
    Department of Internal Medicine, Showa University Kouto Toyosu Hospital
  • HANADA Ryuzo
    Sumida Hospital, SOUSEIKAI
  • ISHIWATA Kazuya
    Pharmacokinetics and Analysis Laboratory, Pharmaceutical Research Center, Pharmaceutical Research Division, Meiji Seika Pharma Co., Ltd.
  • MORITA Jun
    Clinical Research Operation Department, Development Division, Meiji Seika Pharma Co., Ltd.

Bibliographic Information

Other Title
  • <b>日本人健康成人男性を対象としたフェンタニル1日用テープの麻薬拮抗薬非併用下における生物学的同等性試験 </b>

Description

<p>FENTANYL Tape for 1 Day ⌈MEIJI⌋ is a generic drug of OneDuro® Patch (Janssen Pharmaceutical K.K.) under development by Meiji Seika Pharma Co., Ltd. and Yutoku Pharmaceutical Ind. Co., Ltd. The generic drug contains the same active ingredient fentanyl at the same dose in the same dosage form (transdermal absorption) as the original drug. In this study, 32 healthy male Japanese adults were recruited as subjects. Each subject applied a FENTANYL Tape for 1 Day 0.84 mg ⌈MEIJI⌋ and a OneDuro® Patch 0.84 mg once in a crossover manner, without concomitant use of antinarcotic. Bioequivalence of these drugs was investigated by analyzing pharmacokinetic parameters (Cmax and AUC0→t) as primary endpoints calculated from serum fentanyl concentration profiles in all 32 subjects. The results confirmed bioequivalence of the two products. Secondary endpoints including pharmacokinetic parameters such as AUC0→∞, MRTt and kel also supported bioequivalence of the two products. When a FENTANYL Tape for 1 Day 0.84 mg ⌈MEIJI⌋ or a OneDuro® Patch 0.84 mg was applied once for 24 hours without concomitant use of antinarcotic, there were no adverse events such as cutaneous reactions at the application site.</p>

Journal

References(2)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top